Disclosed are antibodies that block the binding of fibronectin protein to fibronectin. Also disclosed are site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB genes of Staphylococcus aureus , the fnbA and fnbB genes of Streptococcus dysgalactiae , and the sfb gene of Streptococcus pyogenes , and nucleic acid segments encoding these peptides and epitopes. The anti-(fibronectin binding site) antibodies, peptides and epitopes that give rise to antibodies that block the binding of fibronectin binding proteins to fibronectin, and DNA segments encoding these proteins and are of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of streptococcal and staphylococcal colonization in animals or humans. These. DNA segments and the peptides derived therefrom are proposed to be of use directly in the preparation of vaccines and also for use as carrier proteins in vaccine formulations.
1. A method of treating a Staphylococcus aureus infection in a human or animal, comprising administering to said human or animal a therapeutically effective amount of an antibody that is generated against a peptide selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12-55, 57, 59-86 and 88-105.
2. The method of claim 1 , wherein said antibody is administered with a pharmaceutically-acceptable vehicle, diluent, or excipient.
3. The method of claim 1 , wherein said antibody is administered to a human or animal suspected of having a Staphylococcus aureus infection.